Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the US, Canada and Mexico. The data was presented at the eighth International Kidney Cancer Symposium in Chicago. The candidate demonstrated efficacy, safety and tolerability in metastatic renal cell carcinoma (RCC) patients whose disease progressed after failing treatment with both a VEGF (vascular endothelial growth factor) receptor inhibitor and an mTOR (mammalian target of rapamycin) inhibitor. Even though the drug was well-tolerated, the most common adverse events were gastrointestinal discomfort and fatigue. RCC is the most common of all kidney tumors, accounting for 85% of the cases. The advanced form of the disease is resistant to standard therapies such as radiation and chemotherapy. The initial treatment in most cases ...

Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the US, Canada and Mexico. The data was presented at the eighth International Kidney Cancer Symposium in Chicago. The candidate demonstrated efficacy, safety and tolerability in metastatic renal cell carcinoma (RCC) patients whose disease progressed after failing treatment with both a VEGF (vascular endothelial growth factor) receptor inhibitor and an mTOR (mammalian target of rapamycin) inhibitor. Even though the drug was well-tolerated, the most common adverse events were gastrointestinal discomfort and fatigue. RCC is the most common of all kidney tumors, accounting for 85% of the cases. The advanced form of the disease is resistant to standard therapies such as radiation and chemotherapy. The initial treatment in most cases ...

Yesterday, Keryx Biopharmaceuticals Inc. (KERX) announced positive long-term results from an open-label extension trial of its kidney drug, Zerenex. This oral, iron-based compound treats elevated serum phosphorous levels (hyperphosphatemia) in patients with end-stage renal disease (ESRD) on dialysis.

Results revealed that serum phosphorous was well-controlled under the drug’s effect. The mid-stage trial involved 29 patients in Taiwan who were followed for a year. Prior studies of the drug did not exceed 28 days.

The study also indicated that Zerenex could maintain phosphorus content at a normal level when used over an extended period of time. Additionally, signs of potential iron overload in the blood were not displayed. Zerenex is expected to enter a late-stage study at the end of the year.

As per data from the US Renal Data System, America has nearly 485,000 ESRD patients. This is projected to rise to about 785,000 by 2020. The majority

...

DrStockPick.com Stock Report!

Wednesday August 5, 2009

**************************************************************

The Procter & Gamble Company (NYSE:PG) announced diluted net earnings per share for the fiscal year ending June 30, 2009 of $4.26, up 17 percent and exceeding the Company’s guidance range of $4.20 to $4.25. Core EPS, which excludes the current year impact from the sale of the Folgers business and certain tax adjustments in the prior fiscal year, increased eight percent versus fiscal 2008. For the April - June quarter, diluted net earnings per share were $0.80, above the Company’s guidance range of $0.74 to $0.79 for the quarter.

China Nepstar Chain Drugstore Ltd. (NYSE: NPD), the largest drugstore chain in China based on the number

...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

AEterna Zentaris Inc. (AEZS) Alleghany Corp. (Y) Amerisafe Inc. (AMSF) AXA (AXA) Banco Bilbao Vizcaya Argentaria SA (BBV) Bio-Imaging Technologies Inc. (BITI) Capitol Federal Financial (CFFN) Cardiome Pharma Corp. (CRME) CBIZ Inc. (CBZ) Cincinnati Bell Inc. (CBB) Conn's Inc. (CONN) Dean Foods Co. (DF) Denison Mines Corp. (DNN) Flanders Corp. (FLDR) GeoEye Inc. (GEOY) HMS Holdings Corp. (HMSY) Innovative Solutions & Support Inc. (ISSC) Inverness Medical Innovations Inc. (IMA) Investors Bancorp Inc. (ISBC) IPC The Hospitalist Co. Inc. (IPCM) Javelin Pharmaceuticals Inc. (JAV) Jos. A. Bank Clothiers Inc. (JOSB) Kaman Corp. (KAMN) Kao Corp. (KCRPY) La Jolla Pharmaceutical Co. (LJPC) Lancaster Colony Corp. (LANC) Life Partners Holdings Inc. (...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Aaron Rents Inc. (RNT) AEterna Zentaris Inc. (AEZS) Alleghany Corp. (Y) Aradigm Corp. (ARDM) ARM Holdings Plc. (ARMH) Banco Bilbao Vizcaya Argentaria SA (BBV) CombinatoRx Inc. (CRXX) CSG Systems International Inc. (CSGS) CTI Industries Corp. (CTIB) El Paso Pipeline Partners L.P. (EPB) Enersis S.A. (ENI) Ensign Group Inc. (ENSG) FPIC Insurance Group Inc. (FPIC) GeoEye Inc. (GEOY) ITT Educational Services Inc. (ESI) Kaman Corp. (KAMN) Labopharm Inc. (DDSS) Longtop Financial Technologies Ltd. (LFT) Maiden Holdings Ltd. (MHLD) Noven Pharmaceuticals Inc. (NOVN) Open Text Corp. (OTEX) ORBCOMM Inc. (ORBC) Orexigen Therapeutics Inc. (OREX) OSG America L.P. (OSP) PetMed Express Inc. (PETS) Richardson Electronics Ltd. (RELL) Thomson Reuters Plc. (RELL) ...